✅List of 40 Companies which delivered strong Q3
Ceinsys Tech
Frontier Springs
Associated Alcohol
RBZ
Sky Gold
Max Estates
V2Retail
India Shelter
MCX
ICIL
Pearl Global
AWFIS
TD Power
Skipper
Kalyan Jewellers
PN Gadgil
Home First
Prudent
Anand Rathi
Capri Global
Supriya Life
Sunteck Realty
Dam Capital
Signature Global
Godfrey Philips
JSW Infra
Muthoot Fin
Senores Pharma
Aeroflex
Ami Organics
Kfin Tech
Techno Electric
Blue Jet
PGEL
MPS
Goldiam
Vishnu Chem
Jindal Drilling
J.G. Chemical
Newgen
List shared only for informational purposes
Which one looks interesting at current valuations ?
In coming years, will more than quadruple our investment in Assam to ₹50,000 cr, Reliance will put AI-ready centres in Assam
Will double Reliance stores in assam to 800 from 400 in 5 years
Mukesh Ambani says at
Onesource Specialty Pharma says
Q4FY25 EBITDA will hit $20mn
3 year Guidance
👉 EBITDA at $160mn (40% margins)
👉 Will be debt free
See a big opprounity in GLP 1
4. Welspun Enterprise Ltd
⚡️Water and Wastewater Treatment Projects
They are involved in large-scale water supply
⚡️Large Water Treatment Plants:
A prominent example is their involvement in the 2,000 MLD (million liters per day) Water Treatment Plant at Bhandup Complex in Mumbai
👉Water treatment projects undertaken by the company
Welspun Enterprises has also secured a contract for the design and construction of a tertiary treated water conveyance tunnel from the Dharavi Wastewater Treatment Facility to the Ghatkopar Wastewater Treatment Facility
👉Water treatment growth strategies
⚡️Technological Advancement and Innovation:
Thermax invests in developing advanced water treatment technologies
👉Key metrics
⚡️Market Cap: ₹ 6,008 Cr.
⚡️Current Price: ₹ 436
⚡️Stock P/E: 18.4
⚡️ROCE: 18.4 %
⚡️ROE: 12.6 %
⚡️Debt to equity: 0.50
⚡️Profit Var 3Yrs: 31.6 %
⚡️Sales growth 3Years: 23.4 %
2. Thermax Ltd
⚡️Comprehensive Water and Wastewater Solutions:
Thermax provides a wide range of solutions, including water treatment, wastewater treatment
⚡️Industrial and Urban Focus:
Thermax is concentrating on the urban segment, which encompasses industrial
👉Water treatment projects undertaken by the company
Thermax provides a wide range of water and wastewater treatment solutions, catering to diverse industrial and municipal needs
👉Water treatment growth strategies
⚡️Technological Advancement and Innovation:
Thermax invests in developing advanced water treatment technologies
👉Key metrics
⚡️Market Cap: ₹ 39,212 Cr.
⚡️Current Price: ₹ 3,290
⚡️Stock P/E: 64.5
⚡️ROCE: 16.9 %
⚡️ROE: 14.2 %
⚡️Debt to equity: 0.32
⚡️Profit Var 3Yrs: 33.8 %
⚡️Sales growth 3Years: 24.8 %
👉Water treatment projects undertaken by the company
Welspun Enterprises has also secured a contract for the design and construction of a tertiary treated water conveyance tunnel from the Dharavi Wastewater Treatment Facility to the Ghatkopar Wastewater Treatment Facility
👉Water treatment growth strategies
⚡️Technological Advancement and Innovation:
Thermax invests in developing advanced water treatment technologies
👉Key metrics
⚡️Market Cap: ₹ 6,008 Cr.
⚡️Current Price: ₹ 436
⚡️Stock P/E: 18.4
⚡️ROCE: 18.4 %
⚡️ROE: 12.6 %
⚡️Debt to equity: 0.50
⚡️Profit Var 3Yrs: 31.6 %
⚡️Sales growth 3Years: 23.4 %
⭐️ Waste 💦 Water Treatment Has Huge Growth Opportunity in India 🇮🇳
👉 4 Stocks To Focus From Waste 💦 Water Treatment 👇
KEI IND FY27 Guidance Revenues of Rs.13400cr & PAT of Rs.1000cr - inline with MS estimates
Читать полностью…
Expect substantial order wins over next few months between Naval Platforms, Next Gen Corvettes & the P17 Bravo Ships
Orderbook will grow from 25,000 to 40,000 cr in next 1 year with Rev CAGR of 25% PRHari of GRSEL discusses growth plans as well as export opportunity
Says export contribution will increase from 4.5% to 10%
11 Key Risks & Challenges
⚠️ Regulatory Compliance Risks – Continuous adherence to USFDA & global regulatory norms is critical
⚠️ Pricing Pressure & Competition – Generic price erosion in the US & regulated markets could impact margins
⚠️ Customer Concentration Risk – Top 5 clients contribute ~65% of revenue, making diversification essential
⚠️ Debt & Leverage Risk – D/E at 1.26, higher than ideal, but manageable for expansion
⚠️ Global Economic Conditions – Slowdowns in key export markets could impact revenue growth
📌Senores Pharma’s strong CDMO contracts, diversification strategy, and expanding product portfolio help mitigate risks
9 Valuation & Key Metrics
📢 Does It Pass Fundamental Investment Screening?
Refer below image
✅ Passes 4/9 Key Investment Filters
❌ Fails in P/E, D/E & PB Ratio
(NO buy/Sell recommendation)
📊 Positives:
✅ Exceptional Profit Growth (162.6% YoY) -Strong earnings expansion
✅ Strong ROE (25.2%) - Efficient capital utilization ✅ No Pledged Shares -Zero risk of share dilution ✅ Growing CDMO & API Business - Expansion driving future growth
⚠️ Concerns:
❌High P/E (82.3) - Valuation premium due to growth potential
❌Higher Debt to Equity (1.26) - Expansion driven leverage
❌ROCE (11.5%) Below Ideal - Needs improvement in capital efficiency
NO buy/Sell recommendation.
📌 Senores Pharma is a Not a textbook perfect fundamental stock, but a high-growth business with strong financials with strong profitability & expansion potential. Investors should monitor leverage and efficiency improvements.
7 Financial Performance
📊 Quarterly Performance (Q3 FY25)
🔹Revenue: ₹106.4 Cr (⬆️ 35.2% YoY)
🔹EBITDA: ₹29.1 Cr (⬆️ 91.8% YoY)
🔹EBITDA Margin: 27.3% (⬆️ 810 bps)
🔹Profit Before Tax (PBT): ₹22.5 Cr (⬆️ 128.1% YoY)
🔹Profit After Tax (PAT): ₹17.2 Cr (⬆️ 142.3% YoY)
🔹PAT Margin: 16.1% (⬆️ 710 bps)
🔹Earnings Per Share (EPS): ₹6.14 (vs. ₹2.52 in Q3 FY24)
📈 Nine-Month Performance (9M FY25)
🔹Revenue: ₹288.1 Cr (⬆️ 157% YoY)
🔹EBITDA: ₹74.3 Cr (⬆️ 287% YoY)
🔹EBITDA Margin: 25.8% (⬆️ 870 bps)
🔹Profit Before Tax (PBT): ₹52.9 Cr (⬆️ 305% YoY)
🔹Profit After Tax (PAT): ₹40.7 Cr (⬆️ 162% YoY)
🔹PAT Margin: 14.1% (⬆️ 30 bps)
🔹Earnings Per Share (EPS): ₹14.56 (vs. ₹5.86 in 9M FY24)
💰 Financial Strength
🔹Low Debt: Strong balance sheet with net cash-positive position .
🔹Healthy Order Book: Strong CDMO pipeline ensuring sustained growth.
📌Senores Pharmaceuticals is witnessing robust financial growth, driven by strong CDMO expansion, increasing revenue streams, and a healthy financial position.
5 Senores Key Clients & Partnerships
♻️Long-Term Partnerships Driving Growth
CDMO/CMO Revenue Contribution Growing Rapidly
🔹FY24: CDMO accounted for ~24% of regulated market revenue .
🔹FY25 Target: CDMO revenue expected to reach $25-30 million (~₹210-250 Cr)
📊Top Clients & Contribution:
🔹Top 5 Clients’ Contribution: ~65% of revenue from regulated market
🔹CDMO Business Expanding: 21 commercialized products, 69 in the pipeline
🔹Long-Term Contracts: 5-7 year agreements with leading global pharmaceutical companies
🏆Key Clients (Global Pharma Companies):
1️⃣Ajanta Pharma (Regulated & Emerging Market Partner)
2️⃣Dr. Reddy’s (CDMO/CMO & Emerging Market Distribution)
3️⃣Sun Pharma (API Supply & Emerging Market Business)
4️⃣Cipla (Injectables & Emerging Market Distribution)
5️⃣Mankind Pharma (Regulated & Emerging Market Supply Agreements)
6️⃣Jubilant Cadista (US Market Partnerships & CDMO Business)
7️⃣Ambica, Amici Pharmaceuticals, Cintex, Mint Pharmaceuticals, La Renon, Prasco, RiteMED, Shalina (Various Market Partnerships)
🚀Emerging Partnerships:
🔹Expanding CDMO/CMO deals in US, Canada & UK (Multiple Clients, Details Not Disclosed)
🔹Increased penetration in CIS, Latin America & Southeast Asia (Distributor Agreements in Place)
🏛Government & Institutional Collaborations:
🔹Supplying Critical Care Injectables to Multi-Specialty Hospitals (India & Emerging Markets)
🔹Targeting US Government Supply Contracts via Buy American Act (BAA) Compliance (US Market)
📌 Strong client retention, growing CDMO/CMO partnerships, and an expanding product pipeline position Senores for sustainable long-term growth
3 Revenue Model & Contribution
🔹Revenue Model:
1️⃣ Direct Sales – Supplying pharmaceutical products to distributors, hospitals, and government agencies.
2️⃣ Long-Term Contracts – CDMO/CMO agreements with multinational pharma companies for sustained revenue.
3️⃣ Licensing & Partnership Model – Revenue from licensing out ANDAs and in-licensing partnerships.
🔹Revenue Contribution (By Business Segment):
1️⃣ Regulated Markets (US, Canada, UK): 64%
2️⃣ Emerging Markets (40+ countries): 30%
3️⃣ API & Injectables Business: 6%
🔹Core Raw Materials Used:
1️⃣ Active Pharmaceutical Ingredients (APIs) – Both in-house and outsourced for cost efficiency.
2️⃣ Excipients & Formulation Components –Essential raw materials for tablets, capsules, and injectables.
3️⃣ Packaging Materials – Blister packs, vials, and sterile containers for regulated and emerging markets.
📌 A well-diversified revenue model with strong CDMO partnerships and a global presence ensures sustained growth for Senores!
1 Who is Senores Pharmaceuticals?
📍Company Overview:
🔹Founded: 2017
🔹Headquarters: Ahmedabad, India
🔹Business Model: Research-driven pharmaceutical manufacturing & CDMO/CMO services
🔹Presence: Strong foothold in regulated markets (US, Canada, UK) + 40+ emerging markets
🔹Manufacturing Plants: USFDA-approved facility in Atlanta, US + WHO-GMP facility in India
🔹Total Installed Capacity: 1.2 billion units (US) + 1.9 billion units (India) + 50 million injectables
🔹Market Position: Fast-growing player in global pharmaceuticals, expanding CDMO/CMO presence
🏢 Subsidiaries & Business Divisions:
🔹Senores Pharmaceuticals Inc. (100% Subsidiary) – ANDA holding company for US operations
🔹Havix Group Inc. (66.58% Subsidiary) – CDMO & Generic Formulations for US & Canada
🔹Ratnatris Pharmaceuticals Pvt. Ltd. (69% Subsidiary) – Manufacturing & marketing in emerging markets
📌 With a robust product pipeline, CDMO expansion, and strong regulatory market presence, Senores Pharma is set for explosive growth.
EPL limited says
👉 Indorama will nominate 1 board member, financial investor as of now with strategic motive
Guidance for business
🎯 Revenue growth in double digits with margin expansion
🎯 ROCE will head towards 20%
AGARWAL INDUSTRIAL GUIDANCE
Revenue: Targeting 20%+ YoY growth in revenue and volume.
Earnings: Aiming for 20% EPS CAGR, aligned with historical growth.
ROCE & ROI: Maintaining ~20%, consistent with past trends.
Industry: Indian bitumen market to hit $6.8B by 2032 (4.0% CAGR), driven by infrastructure projects. Bitumen imports rose 31% in 2023 to 3.42M tons.
GOPAL SNACKS Says See Good Growth In Both Traditional & Western Snacks
Recovered 65-70% Revenue From The Fire That Broke Out In The Factory In December
Fire Incident Is One Of The Reason For Margin Pressure
GOPAL Snacks Says Expanding Distributors In Jharkhand, UP, Telangana & More
Change Packaging Size Will Support The Margins - NDTV PROFIT
3. Va Tech Wabag Ltd
⚡️Drinking Water Treatment:
Providing clean and safe drinking water through various treatment processes.
👉Water treatment projects undertaken by the company
They recently secured a significant order worth Rs 3,251 crore for a sewage treatment plant in Riyadh, Saudi Arabia. This project is part of Saudi Arabia's "Vision 2030" initiative
👉Water treatment growth strategies
⚡️Focus on Sustainable Solutions:
The company is heavily invested in technologies that promote water conservation, recycling, and reuse
⚡️Expanding Global Presence:
👉Key metrics
⚡️Market Cap: ₹ 8,774 Cr.
⚡️Current Price: ₹ 1,411
⚡️Stock P/E: 32.8
⚡️ROCE: 19.8 %
⚡️ROE: 13.8 %
⚡️Debt to equity: 0.22
⚡️Profit Var 3Yrs: 32.5 %
⚡️Sales growth 3Years: 0.26 %
1. Jash Engineering Ltd
⚡️Water and Wastewater Treatment Plants:
They manufacture a wide range of equipment used in these plants.
⚡️Storm Water Pumping Stations:
Providing solutions for managing storm water.
👉Water treatment projects undertaken by the company
They provide crucial components like water control gates, screens, valves, and treatment process equipment.
👉Water treatment growth strategies
⚡️Expanding Product Portfolio:
Jash Engineering offers a wide range of products for various water-related applications, including drinking water
👉Key Metrics
⚡️Market Cap: ₹ 3,253 Cr.
⚡️Current Price: ₹ 520
⚡️Stock P/E: 36.2
⚡️ROCE: 25.1 %
⚡️ROE: 22.6 %
⚡️Debt to equity: 0.29
⚡️Profit Var 3Yrs: 29.9 %
⚡️Sales growth 3Years: 19.9 %
GRSE says
Guidance
🎯 Expect 25% revenue CAGR
🎯 At 8.5% PAT margins, FY27e Net Profit of Rs.600cr looks achievable
🎯 Orderbook headed to Rs.40k cr vs sub Rs.25k cr now
🎯 Exports will move to 10% vs zilch a few years ago
PREMIER POLYFILMS PROMOTOR REGULALRY BUYING RECENT MARKET FALL
Читать полностью…
10 Industry Outlook & Market Opportunity
🔹Global Pharma Market Growth:
✅ $1,635 Bn in 2023 → $2,251 Bn by 2028 (CAGR 6.6%)
✅ Regulated pharma market to dominate with 77% share by 2028
🔹CDMO Market Expansion:
✅ CDMO market growing at 7.7% CAGR, faster than the overall pharma industry
✅ US accounts for ~40% of the global CDMO/CMO market
🔹Emerging Market Growth:
✅ ₹376.3 Bn in 2023 → ₹541 Bn by 2028 (CAGR 7.5%)
✅ Rising demand for specialty & complex generics in CIS, LATAM & SE Asia
🔹Government & Regulatory Tailwinds Supporting Growth:
✅ US Buy American Act (BAA) compliance creating CDMO opportunities
✅ PLI Scheme for bulk drugs & specialty generics in India
✅ Regulatory push for local manufacturing in key export markets
📌 Senores Pharma is positioned to capitalize on the booming CDMO sector, growing demand for specialty generics, and increasing global pharma spending
8 Management Guidance & Future Plans
📌 Order Book & Key Growth Drivers
🔹Strong pipeline with CDMO contracts & regulated market expansion
🔹51 new products in the pipeline, 5 launches in Q4
🔹Emerging markets expansion – 10x growth potential
🔹CDMO/CMO revenue target: $25-30M in FY26
🔹Injectables & API backward integration for cost efficiency
🔹₹200 Cr CapEx planned – Greenfield plant included
🔹Diversification strategy to reduce customer & tariff risks
📝 Senores Q3FY25 ConCall Highlights (Feb 5, 2025)
📊 Financial & Business Growth Guidance :
🔹FY25 revenue target: ₹410-₹440 Cr
🔹FY26 revenue target: ₹670-₹700 Cr
🔹50%-60% top-line growth expected in FY26
🔹PAT expected to double in FY26
🔹EBITDA Margin Expansion: Targeting 28-30%
Capacity Utilization:
🔹FY26: 75% utilization of the expanded API & injectables facility
🔹FY27: 100% utilization with new CDMO contracts
🔹CDMO Business Contribution: Projected to contribute $25-30M in revenue for FY26
Major CDMO Contracts Secured (Q3 FY25):
🔹US-Based Generic Pharma Company – CDMO contract for oral solid formulations
🔹Large European Pharma Player – Long-term CDMO deal for high-margin specialty generics
🔹Emerging Market Supply Contracts – Expanding into CIS, Latin America & Southeast Asia
🔹New CDMO Client Approvals: Additional 5-6 customers in the pipeline
🔹Expanding Portfolio: 28 CGT designated products in pipeline for market exclusivity
Execution Timeline
🔹₹200+ Cr worth of orders to be completed in the next 6-9 months
🔹Accelerated regulatory approvals improving new product pipeline execution
🔹USFDA Inspection Readiness: Ensuring continued compliance & audit preparedness
🔹Emerging Market Growth Acceleration: 131 new filings planned across various geographies
🔄 Order Pipeline Growth & Market Expansion
🔹Growing demand in CDMO, injectables & emerging markets
🔹Exports: Expanding regulated market penetration in US, Canada & UK
🔹Targeting 5 New Market Entries in FY26
🔹Government Contracts Expansion: Exploring opportunities under US Buy American Act compliance
🏭 Expansion & Growth Plans
🔹Chhatral API Facility (FY26): Expanding API production from 25 MTPA to 169 MTPA
🔹Injectables Expansion (US & India): Sterile injectable production ramp-up
🔹New Greenfield Manufacturing Facility (India): Strengthening presence in mid-tier emerging markets
🔹Scaling Production Capabilities: Planned capacity increase to support CDMO & regulated market demand
📉 Competitive Positioning & Market Strength
🔹Rapidly growing player in CDMO & complex generics
🔹80%+ of business from repeat orders, demonstrating strong client retention
🔹R&D Expansion: New research initiatives to strengthen complex formulation pipeline
🌍 Exports & International Market Expansion
🔹Targeting deeper penetration in regulated markets (US, Canada, UK)
🔹Scaling up API & injectables exports to emerging markets (CIS, Latin America, SE Asia)
🔹Entering 2-3 New High-Potential Markets in FY26
🔹New Distribution Partnerships: Strengthening sales channels across strategic geographies
📢 Senores Pharmaceuticals is set for strong growth with capacity expansion, increasing CDMO contracts, aggressive market expansion, strategic acquisitions, and an enhanced focus on R&D-driven high-margin products!
6 Competitive Landscape, Market Positioning & Key Strengths
🌍 Industry Ranking & Competitors:
🔹Ranked as a Fast-Growing Player in the Global Pharmaceutical & CDMO Sector
🔹Lupin (Strong presence in regulated generics & CDMO partnerships)
🔹Aurobindo Pharma (Well-established in regulated markets with a vast ANDA portfolio)
🔹Dr. Reddy’s (Strong CDMO capabilities & presence in high-growth markets)
📈 Market Positioning & Growth Strategy:
🔹Expanding CDMO/CMO Business – 21 commercialized products, 69 in pipeline
🔹Targeting niche generics & high-margin specialty formulations in regulated markets
🔹Emerging Market Growth Strategy – Strengthening presence in CIS, Latin America, & Southeast Asia
🚀 Export Market Expansion:
🔹Growing presence in US, Canada, UK, and 40+ emerging markets
🔹Dedicated regulatory teams to accelerate approvals & international market penetration
💡 Key Strengths of Senores Pharmaceuticals:
1️⃣ Specialty & Complex Product Portfolio – Rapidly built a differentiated portfolio for Regulated Markets
2️⃣ Long-Term Market Arrangements – Established partnerships with pharmaceutical companies in Regulated Markets
3️⃣ Strong Presence in Emerging Markets – Expanding portfolio with specialty & complex products
4️⃣ Robust R&D Capabilities – Driving innovation in niche & high-margin formulations
5️⃣ Advanced Manufacturing Facilities – USFDA-approved plant in the US for Regulated & Semi-Regulated Markets + WHO-GMP certified Indian facility for Emerging Markets
6️⃣ Experienced & Dedicated Management Team
📌 Senores Pharma is strengthening its global footprint with a growing CDMO business, niche product focus, and a strong foundation in R&D and global market reach.
4 Expansion & Growth Strategy
🏭 Current Manufacturing Facilities:
1️⃣ Atlanta, US (USFDA-approved): 1.2 billion units/year (Tablets & Capsules) | Utilizable ~50%
2️⃣ Ahmedabad, India (WHO-GMP): 1.9 billion units/year (Oral Solids + Beta Lactam Orals) + 50 million injectables/year | Utilizable ~65-70%
3️⃣ API Facility (Naroda, India): Manufacturing 16 APIs | Capacity Expansion Planned
🚀 Planned Expansion:
🔹Chhatral API Facility (Under Development): Expanding API capacity from 25 MTPA to 169 MTPA | Expected Completion: FY26
🔹Injectables Expansion (Atlanta, US): Sterile Injectable Production to commence | Expected Completion: 18-24 months
🔹New Greenfield Manufacturing (India): Expansion to serve mid-tier emerging markets | Location & Capacity TBA
📊 Total Installed Capacity: 3.15 billion+ units (including injectables)
📊 Planned Expansion Impact: Significant increase in API production + injectables capacity
📌Strategic capacity expansion = Higher revenue potential & stronger global market presence.
2 Business Model - How Does Senores Make Money?
💊 Pharmaceutical Manufacturing & CDMO/CMO - Core Offerings:
1️⃣ Regulated Market Pharma Business -Developing & manufacturing niche pharmaceutical formulations for US, Canada, and UK markets.
2️⃣ Emerging Market Pharma Business - Expanding presence in 40+ countries with a growing portfolio of specialty generics.
3️⃣ Contract Development & Manufacturing (CDMO/CMO) - Customized formulation, development & manufacturing for global pharma companies.
4️⃣ Critical Care Injectables & API Manufacturing - Backward integration for cost efficiency & supply chain control.
💊Product Portfolio & Business Verticals:
🔹Regulated Markets (US, Canada, UK):
1️⃣ Branded Generics & Complex Formulations - Own & partnered ANDAs (22 commercialized, 24 approved, 51 in pipeline).
2️⃣ Competitive Generic Therapy (CGT) Products - 28 pipeline CGT opportunity molecules.
3️⃣ CDMO/CMO Partnerships - Providing end-to-end drug development, formulation & contract manufacturing services to global pharma giants.
🔹Emerging Markets (40+ countries):
1️⃣ Diverse Portfolio – 267 registered products across CNS, Cardiovascular, Pain Management & Anti-infectives.
2️⃣ Multiple Market Models – Distributor partnerships, own branded generics, & licensing agreements.
🔹API & Injectable Business:
1️⃣ API Manufacturing – Producing critical APIs for regulated & emerging markets.
2️⃣ Critical Care Injectables – Direct hospital supplies via multi-specialty chains (55 products launched).
📌 Senores is a fully integrated pharmaceutical player, leveraging its strong R&D, CDMO expansion, and global market presence for exponential growth
🏥Senores Pharmaceuticals Ltd - A Detailed Analysis
-Senores Pharma is a research driven pharmaceutical company with a strong presence in regulated and emerging markets.
-With robust financial performance and aggressive product pipeline expansion, it is on track to double its revenue in the next two years.
📊 52-Week High / Low: ₹645 / ₹435
💰 Market Cap: ₹2,590 Cr
credit : Sovrenn
One CDMO company Detail analsysis coming up in Few Minutes Stay tuned Here
Читать полностью…
